This site is intended for healthcare professionals
Drug news

APOLLO phase III study of ALN TTR02 (patisiran) in hereditary ATTR amyloidosis with polyneuropathy meets primary endpoints.- Sanofi Genzyme + Alnylam Pharmaceuticals.

Read time: 1 mins
Last updated:22th Sep 2017
Published:21th Sep 2017
Source: Pharmawand
Register free for full access to medthority.com